About the Company
founded in 2013 and based in san diego, calif., arcturus therapeutics is poised to become an industry leader in the application of rnai technologies for the treatment of disease and improved quality of life. the company’s aim is to develop breakthrough technology and novel therapeutics for rare diseases for which there is no adequate treatment. backed by a management team with extensive experience in the discovery and development of therapeutic modalities, arcturus is on the forefront of research and development of nanoparticle sirna drug delivery systems.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ARCT News
Arcturus Therapeutics Holdings Inc (ARCT) Insider Sells Shares
Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT), a biotechnology company focused on the discovery, development, and ...
Arcturus Therapeutics Holdings Inc's Chief Scientific Officer & COO Pad Chivukula Sells ...
Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT), a biotechnology company focused on the discovery, development, and ...
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2023 Earnings Call Transcript
Arcturus Therapeutics Holdings Inc. beats earnings expectations. Reported EPS is $-0.32, expectations were $-1.69. ARCT isn't one of the 30 most popular stocks among hedge funds at the end of the ...
Optimistic Buy Rating for Arcturus Therapeutics Amid Strong Kostaive Vaccine Market Prospects in Japan
In a report released yesterday, Whitney Ijem from Canaccord Genuity maintained a Buy rating on Arcturus Therapeutics (ARCT – Research ...
Arcturus Therapeutics Holdings Inc
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Arcturus (ARCT) Stock Surges 73% in 3 Months: Here's Why
Shares of Arcturus Therapeutics Holdings Inc. ARCT have surged 73% in the past three months compared with the industry’s growth of 10.5%. Last month, the European Commission granted orphan ...
Arcturus Therapeutics files patent for modified human otc protein for treating OTC deficiency
Discover how Arcturus Therapeutics' patent for a modified human OTC protein revolutionizes OTC deficiency treatment with codon optimized mRNA sequences.
Arcturus Therapeutics Holdings Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2023 Earnings Call Transcript
Greetings and welcome to the Arcturus Therapeutics Fourth Quarter and Full Year 2023 Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will ...
Loading the latest forecasts...